SCARB2 mutations in progressive myoclonus epilepsy (PME) without renal failure

Area of Science:

• Genetics
• Neurology
• Molecular Biology

Background:

• Mutations in SCARB2 gene are linked to action myoclonus renal failure syndrome (AMRF).
• Progressive myoclonus epilepsy (PME) is a group of neurological disorders characterized by myoclonic seizures, epilepsy, and ataxia.
• Unverricht-Lundborg disease (ULD) is a severe form of PME with onset in adolescence.

Purpose of the Study:

• To investigate SCARB2 and PRICKLE1 gene mutations in unsolved PME cases.
• To determine if SCARB2 mutations cause PME without renal impairment, particularly ULD-like cases.
• To identify the genetic basis of PME for improved diagnosis and patient counseling.

Main Methods:

• Reviewed 71 PME cases over two decades with no prior molecular diagnosis.
• Classified patients into "ULD-like" and "not ULD-like" based on clinical presentation.
• Performed gene sequencing for SCARB2 and PRICKLE1 after excluding mutations in CSTB.

Main Results:

• Identified SCARB2 mutations in five out of 41 "ULD-like" PME cases.
• No SCARB2 mutations were found in "not ULD-like" PME cases.
• Patients with SCARB2 mutations experienced onset between 14-26 years, with no significant renal failure; PRICKLE1 sequencing revealed no mutations.

Conclusions:

• SCARB2 mutations are a significant cause of PME that mimics ULD, even without renal symptoms.
• Genetic testing for SCARB2 is recommended for PME cases resembling ULD, regardless of renal status.
• Molecular diagnosis of SCARB2-related PME is vital for patient/family counseling due to a potentially worse prognosis than classical ULD.